Hendershot Investments Inc. Acquires Shares of 7,334 GlaxoSmithKline plc (NYSE:GSK)

Hendershot Investments Inc. acquired a new stake in shares of GlaxoSmithKline plc (NYSE:GSKGet Rating) in the fourth quarter, HoldingsChannel.com reports. The firm acquired 7,334 shares of the pharmaceutical company’s stock, valued at approximately $323,000.

A number of other large investors have also recently added to or reduced their stakes in the business. Wedbush Securities Inc. increased its stake in GlaxoSmithKline by 1.5% during the 4th quarter. Wedbush Securities Inc. now owns 15,370 shares of the pharmaceutical company’s stock valued at $678,000 after purchasing an additional 222 shares in the last quarter. MUFG Americas Holdings Corp grew its stake in shares of GlaxoSmithKline by 0.6% in the third quarter. MUFG Americas Holdings Corp now owns 36,721 shares of the pharmaceutical company’s stock worth $1,403,000 after acquiring an additional 237 shares during the period. Key Financial Inc grew its stake in shares of GlaxoSmithKline by 29.6% in the third quarter. Key Financial Inc now owns 1,076 shares of the pharmaceutical company’s stock worth $41,000 after acquiring an additional 246 shares during the period. Hohimer Wealth Management LLC grew its stake in shares of GlaxoSmithKline by 0.4% in the fourth quarter. Hohimer Wealth Management LLC now owns 65,177 shares of the pharmaceutical company’s stock worth $2,874,000 after acquiring an additional 246 shares during the period. Finally, IFP Advisors Inc grew its stake in shares of GlaxoSmithKline by 5.1% in the fourth quarter. IFP Advisors Inc now owns 5,343 shares of the pharmaceutical company’s stock worth $238,000 after acquiring an additional 258 shares during the period. Institutional investors and hedge funds own 26.59% of the company’s stock.

NYSE GSK traded down $0.12 during trading hours on Monday, hitting $46.20. 2,392,668 shares of the company’s stock traded hands, compared to its average volume of 4,974,159. The business’s fifty day moving average price is $43.26 and its two-hundred day moving average price is $42.80. The company has a current ratio of 0.79, a quick ratio of 0.54 and a debt-to-equity ratio of 0.96. The firm has a market capitalization of $117.43 billion, a P/E ratio of 19.25, a P/E/G ratio of 1.88 and a beta of 0.72. GlaxoSmithKline plc has a 52 week low of $37.31 and a 52 week high of $46.97.

GlaxoSmithKline (NYSE:GSKGet Rating) last announced its earnings results on Wednesday, February 9th. The pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.63 by $0.06. The company had revenue of $12.84 billion during the quarter, compared to analyst estimates of $12.62 billion. GlaxoSmithKline had a net margin of 12.90% and a return on equity of 26.33%. During the same period in the previous year, the business posted $0.62 earnings per share. On average, sell-side analysts expect that GlaxoSmithKline plc will post 3.25 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Thursday, April 7th. Shareholders of record on Friday, February 25th were issued a dividend of $0.615 per share. The ex-dividend date of this dividend was Thursday, February 24th. This represents a $2.46 annualized dividend and a yield of 5.32%. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.52. GlaxoSmithKline’s payout ratio is currently 99.17%.

A number of analysts have recently commented on the stock. DZ Bank lowered shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Friday, February 11th. StockNews.com upgraded shares of GlaxoSmithKline from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, March 30th. Stifel Nicolaus assumed coverage on shares of GlaxoSmithKline in a research note on Monday, February 28th. They issued a “hold” rating for the company. Barclays lifted their price target on shares of GlaxoSmithKline from GBX 1,675 ($21.79) to GBX 1,775 ($23.09) in a research note on Thursday. Finally, Zacks Investment Research lowered shares of GlaxoSmithKline from a “buy” rating to a “hold” rating and set a $46.00 target price for the company. in a research report on Tuesday, January 4th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $910.50.

About GlaxoSmithKline (Get Rating)

GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Read More

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSKGet Rating).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.